Amount of qualified sufferers: CDEC discussed the uncertainty in the quantity of individuals with moderately extreme to extreme hemophilia B in Canada suitable for etranacogene dezaparvovec. Medical experts consulted by CADTH indicated that some patients who're labeled as getting mild or reasonable disorder could have a significant bleeding phenotype, which https://donaldi034moo8.mycoolwiki.com/user